Mab-Glyco Technology

Mab-Glyco Technology is a specialized biotechnology company focused on the development of glyco-engineered monoclonal antibodies to enhance their therapeutic efficacy and safety profiles. The company utilizes a proprietary chemoenzymatic glycoengineering (CEG) platform to modify the carbohydrate structures of antibodies, creating homogeneous glycoforms that significantly boost effector functions such as antibody-dependent cellular cytotoxicity (ADCC). By optimizing the glycan profiles of established and novel biologics, Mab-Glyco aims to produce next-generation therapeutics with increased potency and reduced off-target effects. Based in Suzhou's BioBAY, the company leverages its unique enzymatic tools to address the limitations of traditional heterogeneous antibody manufacturing in the fields of oncology and immunology.